2017

MED

IA K

IT

Covering the News of Pharma, Biotech

& Life Science

ddn-news.com

ddncancer.com

2017 MEDIA KIT

2 3

From publishing our first issue in April 2005, to celebrating our 13th year in 2017, DDNews is the only pharmaceutical publication to evolve from a “discovery” base to what we are today: a full service information resource covering the pharmaceutical and biopharmaceutical industry from Discovery through Clinical Trials.

Our Editorial Departments reflect our editorial breadth and demonstrates our functional reach:

PHARMA, BIOTECH & LIFE SCIENCE07.16

JULY 2016 : VOLUME 12 : NUMBER 7PUBLISHED SINCE 2005

CONTRACT SERVICES 35

Answers about alpha-synucleinUniversity of Pittsburgh team uncovers the cause of alpha-synuclein toxicity in Parkinson’sBY KELSEY KAUSTINENPITTSBURGH—Some of the latest research out of the University of Pittsburgh School of Medicine—for which the American Parkinson Disease Association (APDA) was a funding partner—has revealed one of the major rea-sons why alpha-synuclein, a significant com-ponent of the Lewy bodies that characterize Parkinson’s disease, proves toxic to neurons.The findings appeared in Science Transla-tional Medicine in a paper titled “α-Synuclein binds to TOM20 and inhibits mitochondrial protein import in Parkinson’s disease.” The study’s lead investigator was Dr. J. Timo-thy Greenamyre, Love Family Professor of Neurology in Pitt’s School of Medicine and director of the Pittsburgh Institute for Neu-rodegenerative Diseases (PIND), who also serves as the director of the APDA Advanced Center for Parkinson’s Disease Research at PIND and a member of the APDA Scientific Advisory Board.

“It’s really exciting that we have found a mechanism we can target to create new

treatments for this devastating disease,” Greenamyre remarked in a press release. “I’ve been involved in Parkinson’s research for more than 25 years, and the further I go along, the more urgency I feel to trans-

late what we’re doing in the laboratory into something that’s going to make a meaningful difference for people affected by Parkinson’s disease. I believe these findings will have a lot of impact in the Parkinson’s research com-munity. We couldn’t have done it without the support of APDA.”In Parkinson’s disease, the failing neurons contain large clumps of the protein alpha-synuclein. Individuals whose cells produce too much of the protein, or a mutated form, have a high risk of developing Parkinson’s disease due to alpha-synuclein’s toxicity.Alpha-synuclein is a naturally produced protein, but much like amyloid beta—one of the main culprits of Alzheimer’s disease that, it was recently discovered, is generated by the brain as an antibiotic—is not harmful in its normal form and in normal amounts. As Greenamyre tells DDNews, “We do not really understand [alpha-synuclein’s] normal function; however, if we make too much of it—by virtue of our genetic makeup or in response to environmental toxins—it can change its structural characteristics in ways that make it toxic. By the same token, if we have genetic mutations and make abnormal forms of the protein, it may be toxic.” Though

Could microbiome research tool revolutionize drug development?The University of Luxembourg announces ‘breakthrough’ HuMiX organ-on-a-chip model for the human gastrointestinal tractBY JEFFREY BOULEY & RACHEL FLEHINGERLUXEMBOURG CITY, Luxembourg—The human microbiome as an area of research for potential therapeutic value continues to gain popularity and, in that vein, the University of Luxembourg recently announced the publica-tion of a research article in the scientific jour-nal Nature Communications based on research on the interaction between microorganisms in the gut and the human body through the development of the artificial Human-Micro-bial X(cross)-talk model, or HuMiX.HuMiX represents an organ-on-a-chip model for the human gastrointestinal tract, and it has been developed to study the inter-action between the microbiome, the com-munity of all microbial organisms that live in and on our body and the human host—all

in vitro. The model and resulting insights are expected to help provide a better understand-ing of whether changes in the gut’s microbi-ome cause disease, or if such changes are a consequence of the disease.

PITT CONTINUED ON PAGE 9

HUMIX CONTINUED ON PAGE 15

One last study in LEMSCatalyst inches closer to FDA approval for Firdapse BY ZACK ANCHORSCORAL GABLES, Fla.—Weeks after announcing positive results from a Phase 3 study of its drug candidate Firdapse, Catalyst Pharmaceuticals is preparing for yet another study of the drug. The follow-up research is a somewhat unex-pected hurdle that emerged as a result of the U.S. Food and Drug Administration’s (FDA) insistence that Catalyst submit additional positive results from another adequate and well-controlled study in

patients with Lambert-Eaton myasthen-ic syndrome (LEMS), a rare, frequently disabling autoimmune neuromuscular disorder that produces serious muscle weakness and symptoms of autonomic dysfunction.The initial Phase 3 study was a mul-ticenter, randomized, double-blind, placebo-controlled withdrawal trial. All 38 patients enrolled in the study were initially treated with Firdapse followed by treatment with either Firdapse or pla-cebo during a two-week randomization period. The trial was designed so that the CATALYST CONTINUED ON PAGE 31

Next-generation mapping for genomic assemblies .............................................................6Baring the bones .................................................................12MuScreen comes on scene ..............................................35On the cutting edge.............................................................37

PLUS:

Special Focus on Zika

SPECIAL REPORTCell Biology: Sweetening the potIs improved understanding of glycobiology the secret to improved biologics?

42

20

WHAT’S INSIDEDISCOVERY

6

TOOLS & TECHNOLOGY

PRECLINICAL 16

RESEARCH & DEVELOPMENT 12

CLINICAL TRIALS 27DIAGNOSTICS 32

BUSINESS & GOVERNMENT POLICY 37

MARKET NEWS 3EDITORIAL/COMMENTARY 10PRODUCTS & SERVICES 45LATE-BREAKING NEWS 46

An organ-on-a-chip model for the human gastrointestinal tract could do much to reduce reliance on animal models and end up with better results, says the University of Luxembourg. Pictured here is a researcher dealing with cell cultures.

CR

ED

IT: U

NIV

ER

SIT

Y O

F P

ITT

SB

UR

GH

In work that could have a significant impact on treatment of Parkinson’s disease, a team of researchers at the University of Pittsburgh has found two ways to prevent the toxicity that alpha-synuclein causes. Pictured here is the university’s Cathedral of Learning.

Catalyst had thought all that remained for Firdapse to gain FDA approval was one

adequate and well-controlled study, in addition to providing well-supported literature,

but the company was recently directed to do a follow-up study by the FDA.

CR

ED

IT: F

DA

INTERNATIONAL DIGITAL EDITION

MONTHLY NORTH AMERICA PRINT EDITION E-NEWSLETTERS

■■ Bi-weekly e-newsletter

■■ Custom Content Marketing

INTEGRATED WEBSITE

■■ Whitepapers & Application Notes

■■ Research Portals■■ Oncology News■■ Online video library■■ Podcasts

CUSTOM E-MARKETING

■■ Custom html e-blasts

DEPARTMENT AREA OF FOCUS

Discovery■■ Target Identification■■ Biomarker Discovery■■ Lead Identification

R&D■■ Drug Development■■ Target Validation■■ Lead Optimization

Preclinical■■ Lead Optimization■■ ADMET

Clinical Trials■■ Phase I■■ Phase II■■ Phase III

Diagnostics■■ Biomarker Discovery■■ Assay Development■■ Biomarker Validation

Contract Services■■ Research & Development■■ Clinical Trials■■ Manufacturing■■ Regulatory

Business & Government

■■ Approval■■ Registration■■ Manufacturing■■ Regulatory Process

A global pharma readership:DDNews’ circulation is focused on covering the global pharmaceutical and biopharmaceutical industry. While some readers are not employed by “big pharma”, these individuals work in the expanding arena of contract research services, universities, and government agencies like the CDC and NIH: all working on pharma from discovery through clinical trials.Print Circulation............................................................34,298Digital/International Edition Circulation .................5,234e-Newsletter Circulation ............................................82,000+

Our major news vehicles:Monthly Print Edition: Issued monthly to more than 39,000 global pharma professionals encompassing nearly every corner of the globe. DDNews focuses on delivering the news of technology and business, which keeps readers current and relevant in the ever changing pharmaceutical industry. DDNews Online: A twice-monthly e-newsletter that covers breaking business stories and recent significant research findings. DDNews website: A news portal that houses all our in-depth content, industry resources, product literature, white papers and archived print issues. DDNews Cancer Research News: The only independent website dedicated to reporting on the latest news of oncology research, trends and resources. In addition, a special RSS feed puts readers just one click away from up-to-the-minute cancer-related headlines.

Global integrated marketing opportunities to fit every budget :

4 5

Circulation Demographic Analysis

FIELD & DISCIPLINE

TOTAL

PERCENT OF TOTAL

Bioanalytical Chemistry 16,337 41.3%

Biochemistry 16,982 43.0%

Cell Biology 16,757 42.4%

Clinical Diagnostics 14,798 37.4%

Development/Manufacturing 13,631 34.5%

Genomics/Genetics 13,378 33.8%

Medicinal Organic Chemistry 16,806 42.5%

Microbiology 14,998 37.9%

Molecular Biology 12,767 32.3%

Neuroscience 17,231 43.6%

Oncology 13,385 33.9%

Pharmacology 11,158 28.2%

Proteomics/Protein Chemistry 7,825 19.8%

Toxicology 7,129 18.0%

PRODUCTS USED

TOTAL

PERCENT OF TOTAL

ADME/TOX 12,391 31.3%

Assay Development 19,388 49.0%

Bioinformatics 18,717 47.3%

Cellular Analysis 19,317 48.9%

Cell/Tissue Culture 18,608 47.1%

Chromatography 27,048 68.4%

Crystallography 18,377 46.5%

DNA Sequencing 19,054 48.2%

Electrophoresis 16,348 41.4%

Epigenetics 23,326 59.0%

Flow Cytometry 18,416 46.6%

Fluorescence 20,038 50.7%

Gene Expression 18,279 46.2%

Genotyping 19,337 48.9%

HPLC 20,677 52.3%

HTS 18,701 47.3%

Image Analysis 17,799 45.0%

Immunology 15,638 39.6%

Label Free Detection 16,498 41.7%

Mass Spectroscopy 26,395 66.8%

Micro Arrays 17,201 43.5%

Microplate Analysis 18,677 47.2%

Nucleic Acid/ Oligos 17,900 45.3%

PCR 19,243 48.7%

qPCR 18,602 47.1%

Protein Expression 17,928 45.4%

Proteomics 18,016 45.6%

Purification 18,580 47.0%

RNAi/siRNA 18,175 46.0%

Stem Cell 24,728 62.6%

Translational Research 18,598 47.0%

JOB TITLE

TOTAL

PERCENT OF TOTAL

Academic Department Head/Chair 462 1.2%

CEO/President/Executive 1,356 3.4%

Consultant 361 0.9%

Group or Section Leader 2,944 7.4%

Lab Director/Lab Mgr./Dept. Mgr. 5,769 14.6%

Principal Investigator 3,914 9.9%

Production/Process Engineer 623 1.6%

Professor/Instructor 1,032 2.6%

Research Assistant/Grad Student/Post Doc 2,298 5.8%

Research Director/VP of Research 3,209 8.1%

Research Scientist 17,253 43.6%

Other 311 0.8%

INDUSTRY

TOTAL

PERCENT OF TOTAL

Pharmaceutical 17,799 45.0%

Biopharmaceutical 9,005 22.8%

Biotech 3,978 10.1%

Consulting firms 457 1.2%

Contract Research Manufacturing 1,068 2.7%

Government 1,151 2.9%

Clinical Research/Hospital/Medical Center 1,881 4.8%

Private Research/Independent 949 2.4%

University/College 3,099 7.8%

Other 145 0.4%

6 7

Circulation Geographic Analysis

* All USA copies are print edition, all others delivered digitally.

CENTRAL/SOUTH AMERICA

TOTAL

PERCENT OF TOTAL

Argentina 20 0.1%

Brazil 79 0.2%

Chile 30 0.1%

Colombia 10 0.0%

Costa Rica 2 0.0%

Ecuador 4 0.0%

Nicaragua 5 0.0%

Panama 3 0.0%

Peru 11 0.0%

Other 19 0.0%

183 0.5%

ASIA/PACIFIC

TOTAL

PERCENT OF TOTAL

Afghanistan 3 0.0%

Australia 130 0.3%

China 181 0.5%

Hong Kong 77 0.2%

India 407 1.0%

Indonesia 21 0.1%

Malaysia 109 0.3%

New Zealand 27 0.1%

Philippines 20 0.1%

Republic of Korea 257 0.7%

Singapore 111 0.3%

Taiwan 55 0.1%

Thailand 31 0.1%

Other 11 0.0%

1,440 3.6%

AFRICA/MIDDLE EAST

TOTAL

PERCENT OF TOTAL

Egypt 61 0.2%

Iran 4 0.0%

Iraq 6 0.0%

Israel 41 0.1%

Jordan 9 0.0%

Lebanon 2 0.0%

Saudi Arabia 18 0.0%

South Africa 107 0.3%

Other 15 0.0%

263 0.7%

TOTAL 39,532 100%

NORTH AMERICA

TOTAL

PERCENT OF TOTAL

Canada 428 1.1%

United States 33,759 85.4%

Mexico 111 0.3%

34,298 86.8%

EUROPE

TOTAL

PERCENT OF TOTAL

Austria 56 0.1%

Belgium 138 0.3%

Czech Republic 17 0.0%

Denmark 71 0.2%

Finland 71 0.2%

France 361 0.9%

Germany 380 1.0%

Greece 62 0.2%

Hungary 44 0.1%

Ireland 66 0.2%

Italy 192 0.5%

Netherlands 129 0.3%

Norway 28 0.1%

Poland 29 0.1%

Portugal 32 0.1%

Russian Federation 15 0.0%

Spain 201 0.5%

Sweden 128 0.3%

Switzerland 173 0.4%

Turkey 20 0.1%

United Kingdom 1,120 2.8%

Other 15 0.0%

3,348 8.5%

8 9

DDNews Circulation:Top 50 BioPharm/Biotech Companies

DDNews Circulation:Top 50 Pharma Companies

Rank* CompanyPrint Subscribers

e-News Subscribers

Global HQ Base

1 Roche 922 2,163 Switzerland2 Gilead Sciences 706 881 USA3 Amgen 1,085 2,145 USA4 Teva 300 918 Israel5 Novo Nordisk 151 284 Denmark6 Actavis/Allergan 160 286 USA7 Merck KGaA 251 287 Germany8 Biogen 422 1,231 USA9 Valeant 30 64 Canada10 Celgene 325 594 USA11 Shire 78 257 England12 CSL Behring 23 184 USA13 Grifols 10 23 Spain14 Sun Pharma 89 188 India15 UCB 37 217 Belgium16 Regeneron 154 249 USA17 Endo International 128 259 Ireland18 Alexion 28 42 USA19 Dr Reddy's 18 56 India20 Illumina 17 76 USA21 Actelion 30 110 Switzerland22 Novozymes 19 26 Denmark23 IPSEN 4 10 France24 United Therapeutics 88 128 USA25 Jazz 11 32 Ireland26 Vertex 316 612 USA27 Medivation 19 98 USA28 Biomarin 35 65 USA29 Anacor 53 150 USA30 Horizon Pharma 47 111 USA31 Incyte 12 32 USA32 Alkermes 69 225 Ireland33 PDL Biopharma 51 93 USA34 Emergent 105 129 USA35 Acorda Therapeutics 18 40 USA36 Biocon 18 119 India37 Amag Pharma 20 34 USA38 Seattle Genetics 15 60 USA39 The Medicines Co 29 50 USA40 China Biologic 14 26 China41 Ionis 22 80 USA42 Aegerion 85 145 USA43 Nektar Therapeutics 50 91 USA44 Pharmamar 4 8 Spain45 Genmab 4 9 USA46 Spectrum 27 58 USA47 Sciclone Pharma 23 55 USA48 Bavarian Nordic 2 9 Denmark49 Ariad 4 15 Spain50 Morphosys 6 14 Germany

Rank* CompanyPrint Subscribers

e-News Subscribers

Global HQ Base

1 Pfizer 2,023 2,571 USA2 Novartis 1,073 1,947 Switzerland3 Roche 922 2,163 Switzerland4 Merck & Co. 1,357 2,706 USA5 Sanofi SA 1,452 2,956 France6 Gilead Sciences 706 881 USA7 Johnson & Johnson 1,526 2,698 USA8 GlaxoSmithKline 1,271 2,598 England9 AstraZeneca 1,858 2,652 England10 AbbVie 88 612 USA11 Amgen 1,085 2,145 USA12 Allergan 115 363 USA13 Teva Pharmaceutical Industries 300 918 Israel14 Novo Nordisk 151 284 Denmark15 Eli Lilly and Co. 990 1,973 USA16 Bayer 424 1,278 Germany17 Bristol-Myers Squibb 1,320 2,590 USA18 Takeda Pharmaceutical Co. 64 378 Japan19 Boehringer Ingelheim 853 1,551 Germany20 Astellas Pharma 35 55 Japan21 Mylan Laboratories 53 122 USA22 Biogen Idec 422 1,231 USA23 Celgene 325 594 USA24 Merck KGaA 251 287 Germany25 Daiichi Sankyo 12 61 Japan26 Valeant 30 64 Canada27 Otsuka 12 60 Japan28 CSL 23 184 Australia29 Baxalta 91 308 USA30 Shire 78 257 Ireland31 Sun 89 188 India32 Les Laboratoires 76 268 France33 Eisal 66 312 Japan34 UCB 37 217 Belgium35 Abbott 936 1921 USA36 Fresenius 25 37 Germany37 Grifols 10 23 Spain38 Chugai 21 42 Japan39 CJ (CheilJedang) 11 24 Korea40 Mallinckrodt 8 19 Ireland41 Sumitomo Dainippon 21 38 Japan42 Endo 128 259 Ireland43 Manarini 15 33 Italy44 Regeneron 154 249 USA45 Alexion 28 42 USA46 Aspen 36 105 South Africa47 Mitsubishi Tanabe 9 28 Japan48 Nestle 147 276 Switzerland49 Meda 28 60 USA50 Hospira 31 66 USA

Source: HS&M Magazine Source: PharmaExec.com

10 11

EDITORIAL PLANNERDATE FOCUS FEATURE SHOW FEATURE DEPARTMENT FOCUS SHOW DISTRIBUTION

January Microbiomics SLAS 2017 ■ Molecular Medicine Tri-Conference ■ SLAS 2017

FebruaryCell BiologyREADEX Ad Study

ToxExpo Cancer Research News ■ PITTCON ■ ToxExpo ■ BioTherapeutics

March AACR ■ AACR ■ Experimental Bio

April NeuroscienceAAIAmerican Association of Immunology

■ AAI ■ PEGS ■ BioMarker Congress

May READEX Ad StudyISSCR, ASCOAmerican Society of Clinical Oncology

CRISPR

■ ISSCR ■ ASCO ■ World Pharma Congress ■ ASMA

June Cancer

July Immuno Oncology Summit Cancer Research News ■ Next Gen Summit ■ Immuno Oncology Summit

AugustStem CellsREADEX Ad Study

Basel Life Science Week ■ Discovery On Target ■ BASEL Life Science Week

September Infectious Diseases ASHG ■ ASHG ■ ELRIG

October SfNNeuroscience

Cancer Research News ■ Neuroscience (SfN)

NovemberSequencing/GWASREADEX Ad Study

ASCBCell Biology

■ ASCB Cell Biology

December Disease Animal Modeling Cancer Research News ■ PepTalk

ISSUE DATE SPACE CLOSING MATERIALS DATE

January 2017 December 1 December 5February 2017 January 3 January 6March 2017 February 1 February 6April 2017 March 1 March 6May 2017 April 3 April 6June 2017 May 1 May 5July 2017 June 1 June 5August 2017 July 3 July 7September 2017 August 1 August 4October 2017 September 1 September 6November 2017 October 2 October 6December 2017 November 1 November 6

12 13

TABLOID PAGE 1-x 4-x 6-x 8-x 12-x 18-x 24-x

Tab Spread $15,810 $14,750 $13,930 $13,280 $12,730 $12,340 $11,930

1/2 Tab Spread $11,810 $11,040 $10,480 $10,020 $9,640 $9,370 $9,070

Tab Page $8,870 $8,500 $8,030 $7,790 $7,480 $7,250 $7,040

1/2 Tab Page $6,910 $6,510 $6,190 $5,920 $5,730 $5,570 $5,410

1/3 Tab Page $5,360 $5,110 $4,850 $4,700 $4,500 $4,400 $4,340

STANDARD PAGE 1-x 4-x 6-x 8-x 12-x 18-x 24-x

Standard Spread $13,450 $12,620 $12,010 $11,470 $11,040 $10,750 $10,420

Standard Page $7,480 $6,860 $6,680 $6,410 $6,120 $5,970 $5,860

2/3 Standard Page $6,330 $5,960 $5,680 $5,460 $5,300 $5,150 $5,020

1/2 Standard Page $5,410 $5,090 $4,900 $4,710 $4,580 $4,440 $4,360

1/3 Standard Page $3,400 $3,200 $3,050 $2,920 $2,820 $2,750 $2,660

1/4 Standard Page $2,950 $2,780 $2,640 $2,550 $2,460 $2,400 $2,330

1/6 Standard Page $2,490 $2,360 $2,250 $2,180 $2,100 $2,060 $2,020

PAGE ONE AD* $3,120 $3,120 $3,120 $3,120 $3,120 ---- ----

*Page One Ad (4.75” width x 1.625” height)TERMS AND CONDITIONS: Cancellation of any contract requires 60 days written notice. ALL RATES ARE NET: All rates include 4/color.

INSERTS & IMPACT PIECES Net per

4 page insert – Standard supplied $10,380 net

2 page insert – Standard supplied $6,450 net

4 page insert – Standard includes printing

$15,840 net

2 page insert – Standard includes printing

$10,820 net

Full page cover tip on $13,950 net

Gatefold – 6 page $33,470 net

SPECIAL POSITIONS Earned rate plus

Cover 2 15%

Cover 3 10%

Cover 4 20%

Consecutive fraction ads 15%

All other guaranteed positions 10%

TRADE SHOW FEATURE SPONSORSHIP = $18,000 net

Sponsorship includes: Two (2) Print ads (standard or tabloid) within Trade Show Feature, sponsored by logo at top of Show Feature section; Front Page Teaser ad – below what’s new; Digital Edition Sponsorship with custom welcome message and logo, and Pre-Show report eblast to 82,000+ subscribers with exclusive leaderboard and skyscraper banner ads.

Rate card #13Advertising Rates NET

14 15

BLEEDS width x height (inches)

Tab Page 10-7/8 x 14-1/8 bleed 10-5/8 x 13-7/8 trim

Half Tab–Horiz. 10-7/8 x 7-3/16 bleed 10-5/8 x 6-15/16 trim

Half Tab–Vert. 5-1/2 x 14-1/8 bleed 5-1/4 x 13-7/8 trim

1/3 Tab–Horiz. 10-7/8 x 5-5/8 bleed 10-5/8 x 5-3/8 trim

1/3 Tab–Vert. 3-9/16 x 14-1/8 bleed 3-5/16 x 13-7/8 trim

Tab Spread 21-1/2 x 14-1/8 bleed 21-1/4 x 13-7/8 trim

Standard Page 8-3/8 x 10-7/8 bleed 8-1/8 x 10-5/8 trim

Standard Spread 16-1/2 x 10-7/8 bleed 16-1/4 x 10-5/8 trim

NON-BLEEDS width x height (inches)Tab Spread 20-1/4 x 12-7/8Tab Page 9-5/8 x 12-7/8Half Tab–Horiz. 9-5/8 x 6-5/16Half Tab–Vert. 4-5/8 x 12-1/21/3 Tab–Horiz. 9-5/8 x 4-7/81/3 Tab–Vert. 2-13/16 x 12-7/8

STANDARD PAGES width x height (inches)Spread (non-bleed) 15 x 10Page (non-bleed) 7 x 102/3 Page 4-9/16 x 101/2 Page–Island 4-9/16 x 7-1/21/2 Page–Horiz. 7 x 4-7/81/2 Page–Vert. 3-3/8 x 101/3 Page–Vert. 2-3/16 x 101/3 Page–Square 4-9/16 x 4-7/81/4 Page–Vert. 3-3/8 x 4-7/81/6 Page–Vert. 2-3/16 x 4-7/8

ISSUE DATE SPACE CLOSING MATERIALS DATE

January 2017 December 1 December 5

February 2017 January 3 January 6

March 2017 February 1 February 6

April 2017 March 1 March 6

May 2017 April 3 April 6

June 2017 May 1 May 5

July 2017 June 1 June 5

August 2017 July 3 July 7

September 2017 August 1 August 4

October 2017 September 1 September 6

November 2017 October 2 October 6

December 2017 November 1 November 6

Production SpecsMECHANICAL SPECS

■■ Acceptable digital file formats: PDF or composite TIFF or EPS files with pictures/art and fonts embedded.

■■ Bleed ads should have 1/8-inch bleed on all sides and crop marks should be offset by 12 pts.

■■ All pictures should be at least 300 dpi at printed size for CMYK and grayscale; 600 dpi for line art.

■■ Total ink density not to exceed 260%. 110 line screen.■■ All color is CMYK. PMS or spot colors are not accepted.■■ Please send color proofs at 100%. Without a proof, DDNews

cannot be held responsible for the optimum outcome of color. SWOP Standards apply.

E-MAIL AD MATERIALSTo ads@ddn-news.com include the advertiser’s name and issue date in the subject line.

FTP AD MATERIALSFor instructions go to www.ddn-news.com/ftp

2017 Production Schedule

16 17

E-Mail banners to: doyle@ddn-news.com E-Mail orders to: gorsline@ddn-news.com

Electronic Advertising Opportunities

REQUIREMENTS: Banners must be in GIF or Animated GIF format only. Banner size as noted above. Banners must be no larger than 20kb in size. No transparent GIF’s or SWF accepted.

Website videos 3 Month Posting $2,920 flat

Feature Technology Sponsorship3 Month Minimum $3,200 per monthAn exclusive sponsorship of all related news articles specific to a “technology” such as qPCR. Included is a 728 x 90 leaderboard, 300 x 250 big box banner, and two product releases which are interspersed within technology editorial.

Whitepapers 3 Month Posting $1,830 net (per unit)

DDNews website ddn-news.comVarious ad sizes are available on the home page and news pages. Ads are placed in rotation. Maximum three deep rotation.Over 60,000 monthly visitors.

Ad Size One Month

3 months per month

6 months per month

12 monthsper month

300 x 100 $3,070 $2,840 $2,610 $2,160

728 x 90 scrolling banner $3,290 $3,070 $2,840 $2,390

300 x 250 Big Box $4,080 $3,860 $3,630 $3,400

728 x 90 Leaderboard $3,860 $3,180 $2,950 $2,610

ADVERTISING RATES (net)DDNews Cancer website ddncancer.comDDNews is the only news publication to have a dedicated website specifically for cancer research and oncology news. Audience is lab managers, and researchers involved in drug discovery & development for cancer. Over 16,000 monthly visitors.

Banners One Month

3 months per month

6 months per month

12 monthsper month

300 x 100 $2,300 $2,080 $1,860 $1,530

728 x 90 scrolling banner $2,520 $2,300 $2,080 $1,860

300 x 250 Big Box $3,280 $3,060 $2,840 $2,520

728 x 90 Leaderboard $2,950 $2,740 $2,520 $2,300

3 Month Cancer Video Posting $2,300 (net)

18 19

Custom HTML E-mailsGet your product custom message out to the DDNews subscriber.

RATES PER MAILINGUp to 5,000 $2,910 (net) 5,000 to 6,500 $3,330 (net)6,500 to 8,000 $3,850 (net)8,000 to 10,000 $4,370 (net)Mailings larger that 10,000 will be quoted$500 net charge for split copy and/or headline per split.

E-Products & ServicesFebruary, May, August, NovemberA quarterly showcase of new products and services, available with an optional imbedded three minute video/product demonstration link.

Distributed by e-mail to 82,000+ qualified recipients.

E-PRODUCTS & SERVICES (per unit)Standard Unit $1,220 (net) Unit With Video $1,930 (net)

E-NewsletterOur biweekly e-newsletter keeps readers around the world informed of late breaking news, updates, analysis, upcoming industry events, and commentary.

Distributed the second and fourth Wednesday of each month to 82,000+ qualified recipients.

REQUIREMENTS: Banners must be in static GIF format only. Banner size as noted above. Banners must be no larger than 20kb in size. No transparent GIF’s or SWF accepted.

ADVERTISING RATES (net)

Ad Size 1x-5x 6x-11x 12+

300 x 100 $2,300 $2,080 $1,860

120 x 600 $3,240 $2,950 $2,740

468 x 60 $4,220 $4,010 $3,680

Custom Content Marketing Combining your news and DDNews to customize your product message.You choose the area of focus/subject (e.g. Cancer, CRISPR, Immunology, etc.) We supply five DDNews stories to fit your subject area; you supply two stories/product features and your leaderboard banner (468 x 60). We then mail to our 82,000+ qualified recipients, and 20,000 of your customers/prospects (optional).

RATE PER MAILINGCCM is available 3 times per month $4500 Leaderboard banner must be static GIF not exceeding 20kb in size.

PodcastsThe DDNews podcast includes: 1. Custom announcement mailing to 82,000+ qualified DDNews recipients and a bonus mailing to 20,000 advertiser supplied contacts (optional).2. Advertiser receives the “read in” to the podcast, i.e. underwriting credit within the podcast3. Placement on DDNews website with 20 word description and company logo.4. It is suggested podcast be formatted as a commentary or a Q&A session.

Podcasts content is subject to DDNews editorial approval. Podcast will be recorded as a “Go-to-Meeting” with our production team. Suggested length is 5 – 10 minutes maximum.

PODCAST RATES: 1 – 5x $4,000 net each6 – 11x $3600 net each12x + $3200 net each

Advertising Sales Representatives NORTHEASTMICHAEL STACK1127 Kristin Drive, Suite 100, Libertyville, IL 60048Tel: 847.922.1799stack@ddn-news.com

MIDWEST/MIDATLANTICRYAN KING1900 N. Hudson, #D, Chicago, IL 60614Tel: 773.414.9292king@ddn-news.com

SOUTHWESTHUTSON LAMBERT212 E. 2nd Street, Suite 202, Pass Christian, MS 39571Tel: 228.452.9683lambert@ddn-news.com

EUROPE, AFRICA, ASIA STEPHANIE PAINTERPainter-Lowe CommunicationsStephanie@painter-lowe.comwww.painter-lowe.comTel: +44 1634 829386

ManagementBRUCE POORMANPresident & Publisherpoorman@ddn-news.com

LAURENCE DOYLEExecutive VP & General Managerdoyle@ddn-news.com

MARGE GORSLINEOperations Managergorsline@ddn-news.com

DDNewsOLD RIVER PUBLICATIONS, LLC.19035 Old Detroit Road, Suite 203 Rocky River, OH 44116Tel: 440.331.6600Fax: 440.331.7563www.DDN-news.com